In a 28-year-old man with type 2 diabetes on metformin, empagliflozin (Jardiance) and tirzepatide (Zepbound) who has an A1c of 12 %, random glucose 311 mg/dL, mild ketonuria, normal bicarbonate and anion gap, eGFR 129 mL/min/1.73 m², triglycerides 525 mg/dL, HDL 27 mg/dL, LDL 86 mg/dL, and is asymptomatic, what are the appropriate management recommendations given his last follow‑up was 6–8 months ago?

Immediate Management of Severe Hyperglycemia with Ketonuria in a Young Adult with Type 2 Diabetes

Urgent Assessment for Euglycemic Diabetic Ketoacidosis

You must immediately evaluate this patient for euglycemic DKA, even though the bicarbonate is normal and the anion gap is not elevated, because the combination of marked glucosuria (>1000 mg/dL), ketonuria (15 mg/dL), and SGLT2-inhibitor therapy creates high risk for this life-threatening complication. 1

• Obtain a point-of-care β-hydroxybutyrate level immediately; a value >3.0 mmol/L confirms DKA regardless of the normal bicarbonate and anion gap, and mandates hospitalization with intravenous insulin and aggressive fluid resuscitation. 1
• The normal bicarbonate (27 mEq/L) and anion gap (12 mEq/L) do not exclude euglycemic DKA in SGLT2-inhibitor users, because these agents promote renal bicarbonate reabsorption that can mask the metabolic acidosis. 1, 2
• Discontinue empagliflozin (Jardiance) immediately and do not restart it until ketonuria has completely resolved on repeat urinalysis and fasting glucose has been consistently 80–130 mg/dL for at least 2 weeks on basal insulin. 3, 1
• Screen for precipitating factors: recent illness, reduced caloric intake (including fasting or low-carbohydrate dieting), alcohol use, or any stressor that increases ketogenesis. 1, 4

Immediate Basal Insulin Initiation

Start basal insulin (glargine or degludec) at 10 units once daily at bedtime tonight, or calculate 0.2 units/kg body weight given the severity of hyperglycemia (HbA1c 12%, glucose 311 mg/dL). 1, 5

• Titrate basal insulin by 2–4 units every 3 days until fasting glucose reaches 80–130 mg/dL without hypoglycemia. 1, 5
• Do not delay insulin initiation; an HbA1c of 12% with random glucose >300 mg/dL and ketonuria represents severe metabolic decompensation that requires immediate insulin therapy to reverse glucotoxicity and preserve β-cell function. 5
• Continue metformin at the current dose (or increase to 2000 mg daily if currently taking less) because it reduces insulin requirements by 20–30%, mitigates insulin-associated weight gain, and carries minimal hypoglycemia risk when combined with basal insulin. 1, 5

Metformin Optimization and Continuation

Increase metformin to 2000 mg daily (1000 mg twice daily with meals) if the patient is currently taking a lower dose, because this provides maximal glucose-lowering efficacy. 5

• Never discontinue metformin when adding basal insulin; stopping it eliminates its cardiovascular mortality benefit, raises insulin requirements, and promotes weight gain. 1, 5
• Metformin is safe to continue at full dose because the patient's eGFR is 129 mL/min/1.73 m², well above the 30 mL/min/1.73 m² threshold for discontinuation. 3, 5
• Monitor for vitamin B12 deficiency after 6–12 months of continuous metformin use, especially if anemia or peripheral neuropathy develop. 3, 5

Tirzepatide (Zepbound) Dose Optimization

Continue tirzepatide and escalate to the maximum therapeutic dose (up to 15 mg weekly) to achieve an additional 0.6–0.8% HbA1c reduction and promote 2–5 kg weight loss. 1, 5

• Do not discontinue tirzepatide; it synergizes with basal insulin by reducing insulin requirements, preventing weight gain, and providing superior glycemic control compared with insulin intensification alone. 1, 5
• Tirzepatide carries minimal intrinsic hypoglycemia risk when used without sulfonylureas, making it safe to continue alongside basal insulin. 5

Empagliflozin (Jardiance) Management

Hold empagliflozin indefinitely until both (1) ketonuria has completely resolved on repeat urinalysis and (2) fasting glucose has consistently been 80–130 mg/dL for at least 2 weeks on basal insulin. 3, 1

• Once these criteria are met, restart empagliflozin 25 mg daily for its proven cardiovascular and renal protective effects, which are independent of glucose lowering. 3, 1
• Educate the patient to stop empagliflozin immediately and seek urgent care if nausea, vomiting, abdominal pain, dyspnea, or reduced oral intake develop, as these are warning signs of euglycemic DKA. 3, 1
• Institute a "sick day protocol": during any acute illness, fasting, or reduced caloric intake, the patient must stop empagliflozin and check blood or urine ketones; if ketones are positive, start basal insulin immediately. 3, 1

Severe Hypertriglyceridemia Management

Initiate high-intensity statin therapy (atorvastatin 40–80 mg daily or rosuvastatin 20–40 mg daily) immediately because type 2 diabetes confers high cardiovascular risk and the patient's triglycerides of 525 mg/dL constitute severe hypertriglyceridemia requiring urgent intervention to prevent acute pancreatitis. 1

• Add fenofibrate 145 mg daily (or gemfibrozil 600 mg twice daily) specifically to lower triglycerides below 500 mg/dL and reduce pancreatitis risk. 1
• Target LDL-C <70 mg/dL; the current LDL of 86 mg/dL exceeds this goal, so intensify statin dose or add ezetimibe as needed. 1
• Advise complete avoidance of alcohol until triglycerides normalize, as alcohol markedly worsens hypertriglyceridemia. 1
• Counsel a strict dietary fat restriction (<15% of total calories) until triglycerides fall below 500 mg/dL. 1
• Expect substantial triglyceride reduction once glycemic control improves; re-measure lipids at 3 months, and if triglycerides remain >200 mg/dL despite good glucose control, continue fenofibrate long-term. 1

Monitoring and Follow-Up Schedule

Schedule a follow-up visit in 1 week to assess ketonuria resolution, review insulin titration, and confirm empagliflozin discontinuation. 1

• Weeks 1–2: Daily fasting glucose checks to guide basal insulin titration; repeat urinalysis to confirm ketone clearance before empagliflozin restart. 1, 5
• Month 1: Review fasting glucose trends, insulin dose adequacy, and hypoglycemia episodes; consider empagliflozin restart if criteria met. 1
• Month 3: Measure HbA1c (target <7%); re-check lipid panel and liver enzymes; add a GLP-1 receptor agonist if HbA1c >7% despite optimized therapy. 1, 5
• Month 6 and beyond: Continue HbA1c monitoring every 3 months until target achieved, then every 6 months; perform annual lipid panel, renal function tests, and comprehensive metabolic panel; schedule yearly dilated eye exam and foot examination. 1, 5

Expected Clinical Outcomes

• Ketonuria resolution within 1–2 weeks once basal insulin is established. 1
• Fasting glucose normalization to 80–130 mg/dL within 2–4 weeks of basal insulin titration. 5
• HbA1c reduction of 2–3% with dual therapy (metformin + basal insulin + tirzepatide), often achieving <7% by 3 months. 5
• Weight loss of 2–5 kg with optimized tirzepatide dosing, counteracting the modest weight gain associated with insulin therapy. 1, 5
• Triglyceride reduction to <200 mg/dL once glycemic control improves and fenofibrate is added. 1
• Normalization of ALT (mild transaminitis at 61 U/L) as glycemic control and weight improve, reflecting resolution of non-alcoholic fatty liver disease. 1

Critical Pitfalls to Avoid

• Do not assume the patient is not in DKA based solely on normal bicarbonate and anion gap; obtain a β-hydroxybutyrate level to definitively exclude euglycemic DKA. 1
• Do not restart empagliflozin until ketonuria has resolved and glucose is stable for at least 2 weeks, as premature restart markedly raises DKA risk. 3, 1
• Do not delay insulin initiation while awaiting oral agents; severe hyperglycemia with ketonuria warrants immediate basal insulin therapy. 1, 5
• Do not discontinue metformin when adding basal insulin unless a specific contraindication exists; it remains foundational therapy throughout intensification. 1, 5
• Do not ignore severe hypertriglyceridemia (>500 mg/dL); urgent lipid-lowering therapy is essential to prevent pancreatitis. 1
• Do not wait beyond 3 months to intensify therapy if HbA1c remains above target, as therapeutic inertia raises complication risk. 1, 5